Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS

被引:145
作者
Seikaly, MG
Ho, PL
Emmett, L
Fine, RN
Tejani, A
机构
[1] NAPRTCS, Hawthorne, NY 10532 USA
[2] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA
[3] EMMES Corp, Rockville, MD USA
[4] New York Med Coll, Valhalla, NY 10595 USA
[5] SUNY Stony Brook, Stony Brook, NY 11794 USA
关键词
chronic renal failure; etiology; treatment;
D O I
10.1007/s00467-003-1158-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
End-stage renal disease (ESRD) is a major cause of morbidity in children. Besides its high cost to society, ESRD carries significant mortality. Chronic renal insufficiency (CRI) often precedes ESRD. Identifying factors that correlate with the rate of progression to ESRD is beneficial in the management of children with CRI. Since 1994 the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) has extended its registry to include children with CRI, defined as creatinine clearance (C-Cr) <75 ml/min per 1.73 m(2). As of January 2001, our database registered 4,666 children (<20 years of age) with CRI. Data analysis showed that at least 40% of patients entered had congenital urological anomalies; 39% of patients were followed for at least 3 years. Follow-up data showed that 31% of all registered patients progressed to ESRD by the end of the reporting period. There was a correlation between CRI and several co-morbid clinical factors: low hematocrit, hypoalbuminemia, hypocalcemia, hyperphosphatemia, and hyperparathyroidism, and the rate of progression to ESRD. Primary clinical diagnosis and the age at entry into registry were additional factors that correlated with the rate of progression to ESRD. The main cause of hospitalization in this registry was infection, which accounted for 45% of hospital admissions. Growth delay measured by standard deviation score at baseline was -1.40 at the time of registration. Our data suggest potential areas of improved care that could impact the onset of ESRD.
引用
收藏
页码:796 / 804
页数:9
相关论文
共 44 条
[11]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483
[12]   EFFECTS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HLA SENSITIZATION AND CELL-MEDIATED-IMMUNITY [J].
GRIMM, PC ;
SINAITRIEMAN, L ;
SEKIYA, NM ;
ROBERTSON, LS ;
ROBINSON, BJ ;
FINE, RN ;
ETTENGER, RB .
KIDNEY INTERNATIONAL, 1990, 38 (01) :12-18
[13]   Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure [J].
Hayashi, T ;
Suzuki, A ;
Shoji, T ;
Togawa, M ;
Okada, N ;
Tsubakihara, Y ;
Imai, E ;
Hori, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (02) :250-256
[14]   Delayed referral of black, Hispanic, and older patients with chronic renal failure [J].
Ifudu, O ;
Dawood, M ;
Iofel, Y ;
Valcourt, JS ;
Friedman, EA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) :728-733
[15]  
Ismail N, 1997, SEMIN NEPHROL, V17, P270
[16]  
Jabs K, 1996, Adv Ren Replace Ther, V3, P24
[17]   Screening for renal insufficiency: is it worth while? is it feasible? [J].
Jungers, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (09) :2082-2084
[18]  
KHAN IH, 1994, Q J MED, V87, P559
[19]   Anaemia in the patient with renal insufficiency: documenting the impact and reviewing treatment strategies [J].
Levin, A .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (02) :292-295
[20]  
Lieberman KV, 1996, J AM SOC NEPHROL, V7, P56